Showing results (41-50 of 93) with videos related to
Sort By:
Pageof 10
Breast (Edinburgh, Scotland)|January 5, 2019
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytesNancy Tray, Jessica Taff, Baljit Singh, et al.Breast Cancer Research and Treatment|September 30, 2010
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survivalSylvia Adams, A Bapsi Chakravarthy, Martin Donach, et al.Breast Cancer Research and Treatment|September 19, 2020
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatmentJiehui Deng, Aatish Thennavan, Suhagi Shah, et al.Cancer Immunology, Immunotherapy : CII|April 6, 2011
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three casesJianda Yuan, Brian Ginsberg, David Page, et al.Proceedings of the National Academy of Sciences of the United States of America|November 17, 2009
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survivalDusan Bogunovic, David W O'Neill, Ilana Belitskaya-Levy, et al.Journal for Immunotherapy of Cancer|April 5, 2025
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancerSylvia Adams, Sandra Demaria, Darawan Rinchai, et al.Breast Cancer Research : BCR|August 3, 2017
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerKomal Jhaveri, Rui Wang, Eleonora Teplinsky, et al.Plos One|October 25, 2013
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancerXinyu Wu, Yirong Li, Jinhua Wang, et al.The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.Journal of Cancer Research and Clinical Oncology|October 3, 2025
Evaluation of the gut microbiome and sex hormones in postmenopausal women with newly diagnosed hormone receptor-positive breast cancer versus healthy women: a prospective case-control studyMaryann Kwa, Grant Hussey, Yelena Novik, et al.Pageof 10